

April 23, 2020



# **New World Provides Updates Regarding Amalgamation Transaction with Perimeter Medical Imaging, Inc.**

## **Perimeter Medical Imaging, Inc. Announces Receipt of \$10 Million Grant**

Vancouver, British Columbia--(Newsfile Corp. - April 23, 2020) - New World Resource Corp. (TSXV: NW) ("New World") is pleased to announce that target RTO company, Perimeter Medical Imaging, Inc. ("Perimeter") announced it has received a \$10.4 million (US\$7.44 million) grant to further develop its AI ImgAssist technology for their OTIS™ device at leading cancer centers in Texas. This funding is granted by the Cancer Prevention and Research Institute of Texas (CPRIT) to support technology development and clinical studies aimed to decrease the reoperation rates for breast cancer patients. The sponsored technology, known as OTIS™ (Optical Tissue Imaging System), is designed to provide real-time information during breast cancer surgery. The platform's ability to deliver ultra-high resolution and sub-surface image volumes across the surface of the removed tissue along with information from existing methods allows surgeons to assess if they have achieved the successful removal of the entire tumor. Should a surgeon identify cancerous cells at the surface of the tissue, they can immediately remove additional tissue from the patient. The OTIS™ technology could lower the financial burden to the healthcare system and become a significant win for some patients, taking away the additional physical and mental trauma caused by the necessity to repeat the surgery. This CPRIT funding will support clinical studies assessing OTIS™ technology and its potential to improve the lives of breast cancer patients.

"The CPRIT award will be transformational for Perimeter as it provides substantial funding for key research projects partnering with world-renowned cancer care centers in Texas to advance our technology in pursuit of our mission to providing solutions that drive better patient care and lower healthcare costs by providing critical information during clinical procedures," said Dr. Anthony Holler, Perimeter's Chairman of the Board of Directors.

New World and Perimeter are also pleased to announce that they have now agreed to a completion goal of late Q2 of 2020 for their amalgamation by way of plan of arrangement (the "Transaction"). The Transaction is an arm's length transaction and will result in a reverse take-over and change of control of New World by the shareholders of Perimeter. The resulting publicly traded company (the "Resulting Issuer") will be named Perimeter Medical Imaging AI, Inc. and its management team will be led by CEO Tom Boon and Perimeter's Chair of the Board, Dr. Anthony Holler.

In connection with the completion goal of late Q2 of 2020, New World and Perimeter have also today agreed to amend and restate the previously announced arrangement agreement dated June 3, 2019 (the "Arrangement Agreement") to extend the outside closing date of the Transaction to December 31, 2020. In addition, the Arrangement Agreement was amended

to set an additional closing condition that Perimeter raise a minimum of \$3.0 million in a concurrent financing immediately prior to and in conjunction with completion of the Transaction as described below.

Further information regarding the Transaction will be contained in a proxy statement and information circular that will be prepared jointly by New World and Perimeter and mailed to securityholders of both companies in due course in connection with annual and special securityholders meetings to be held by both companies.

A copy of the second amended and restated Arrangement Agreement with respect to the Transaction will be filed on New World's profile on SEDAR at [www.sedar.com](http://www.sedar.com).

In addition to the minimum required raise as mentioned above, the Transaction remains subject to customary closing conditions for transactions of this nature as well as all requisite regulatory approvals including approval of both New World's and Perimeter's securityholders, the acceptance of the TSX Venture Exchange and a final order of the Supreme Court of British Columbia as to the fairness of the Transaction. The Transaction cannot close until the required shareholder approvals and regulatory acceptance are obtained.

New World's shares are currently halted from trading and are expected to remain halted pending the completion of the Transaction.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

### **About New World**

New World has cash and marketable securities of approximately \$3.5 million (as of the close of business on December 31, 2019).

### **About Perimeter**

Perimeter is a private Toronto-headquartered company that is developing, with plans to commercialize, advanced imaging tools that allow surgeons, radiologists and pathologists to better assess microscopic tissue structures during a surgical procedure. Perimeter's OTIS™ platform is an FDA-cleared point-of-care imaging system that provides surgeons with real-time, ultra-high resolution, sub-surface image volumes of the margin (1-2 mm below the surface) of an excised tissue specimen.

In addition, Perimeter is developing advanced artificial intelligence/machine learning image assessment tools to increase the efficiency of review. Please refer to Perimeter's website: <https://www.perimetermed.com/>.

### **Contact**

For further information regarding the content of this news release, New World or Perimeter please contact John Lando, President of New World at (604) 669-2701 or by email at [jel@sterlingpac.com](mailto:jel@sterlingpac.com) or Perimeter at (647) 360- 0302 or by email at [contact@perimetermed.com](mailto:contact@perimetermed.com).

## **Cautionary Notice Concerning Forward-Looking Statements**

This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to: the anticipated closing date of the Transaction, the terms and conditions of the Transaction, the anticipated name and management of the Resulting Issuer, the business and operations of Perimeter and the Resulting Issuer, the potential benefits of Perimeter's imaging technologies, the anticipated benefits of Perimeter's CPRIT funding, further information to be provided by Perimeter and New World and the filing of the second amended and restated Arrangement Agreement on SEDAR. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, regulatory, competitive, political and social uncertainties, uncertain capital markets; uncertainties in launching a new product and making sales of OTIS™, beginning commercial manufacturing of OTIS™, and delay or failure to receive shareholder, court or regulatory approvals for the Transaction. There can be no assurance that the Transaction will proceed on the terms contemplated above or at all and that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. New World and Perimeter disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

THIS NEWS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER TO SELL SECURITIES AND NEITHER NEW WORLD OR PERIMETER IS SOLICITING AN OFFER TO BUY THE SECURITIES DESCRIBED HEREIN. THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.